Clinical Trial Update: Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). [Phase 2]

View source ↗

Summary

Phase 2 trial MASTERKEY-115 evaluated talimogene laherparepvec in combination with pembrolizumab for melanoma after progression on prior anti-PD-1 therapy; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Amgen | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-09-09